Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Shares of Cassava Sciences, Inc. SAVA fell sharply in today's pre-market trading after the SEC charged the company, two ...

Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...

The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...